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a guideline-recommended intervention. Approximately 73% of interventions exam-
ined in diabetes CUAs were found to be either cost-saving or below $50,000 per QALY. 
Logistic regression analysis showed that higher-quality CUAs or CUAs conducted 
from the US perspective were more likely to report favorable ratios. Ratios for sur-
gical interventions and interventions recommended by diabetes guidelines were 
more favorable than other intervention types. Of 7,907 eligible patients in Humedica, 
6,500 could be shifted to cost-saving treatments, saving more than $11 million and 
gaining more than 1,800 QALYs. ConClusions: Our findings suggest that most 
diabetes interventions evaluated by CUAs are recommended by practice guidelines 
and may provide good value for money. Our results also indicate that patients and 
the health care system could benefit considerably from shifting to greater use of 
cost-saving interventions.
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objeCtives: The contribution of weight change to the economic burden of T2DM 
is unclear. This study investigated associations between weight change and HCRU 
in patients with T2DM initiating new antidiabetic drug class. Methods: Patients 
with T2DM initiating new antidiabetic drug classes (first-line, switch or add-on) 
between 01/01/05-01/01/12 were identified in UK Clinical Practice Research Datalink 
primary care (PC) records linked with Hospital-Episode-Statistics. Baseline char-
acteristics were assessed before drug class initiation and weight change (index 
date) was observed 6 months after. HCRU was followed up to one year after index 
and included diabetes-related PC contacts and prescriptions, and all-cause hospi-
talisation days. Weight change was categorized as: < 3.0% change (weight-neutral), 
3.0%-5.4% gain (gain+), ≥ 5.5% gain (gain++), 3.0%-5.4% loss (loss+), ≥ 5.5% loss 
(loss++). Comparisons between weight groups were conducted using negative bino-
mial regression. Results: Of 9031 patients with mean age 59.2 years and 57.4% 
men; 54.3% were weight-neutral, 12.0% gain+, 10.2% gain++, 12.8% loss+, 10.7% 
loss++. Mean baseline BMI ranged from 30.1 kg/m2 (gain++) to 33.8 kg/m2 (loss++). 
Follow-up crude mean PC contacts for all patients was 4.6 per person-year (PPY), 
mean prescriptions 15.3 PPY, mean hospitalisation days 1.5 PPY. For the weight-
neutral group, crude mean PC contacts, prescriptions and hospitalisation days were 
4.6, 14.9 and 1.2 PPY, respectively. In initial adjusted comparisons to weight-neutral 
patients, gain++ had more PC contacts, gain+ and gain++ had more prescriptions 
whereas loss+ patients had fewer. Gain+ and loss++ patients had more hospitali-
sation days than weight-neutral patients. ConClusions: T2DM patients gaining 
weight after initiating new antidiabetic treatment may have increased health care 
resource use compared to weight-neutral patients. Higher weight loss, possibly due 
to underlying health problems, may also be associated with increased resource use. 
Causal interpretations of these results require detailed information on social and 
medical factors driving resource use in diabetic patients that were unavailable.
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objeCtives: This study was aimed to estimate the impact of health insurance status 
in adult diabetic patients on health care resource utilization and costs. Methods: 
Patients were identified in the Medical Expenditure Panel for the 2011 cycle and 
were included if they had a diabetes diagnosis and were 18 or older. Insurance 
status was defined as private, public or uninsured. Results: Of the 2,180 patients, 
9% were uninsured, 31% had public health insurance and 60% had private health 
insurance. Uninsured patients were younger, more likely to be a racial minority, in 
the lower income or poor categories, with lower education compared to those with 
private insurance. After age adjustment, they were significantly less likely to be on 
Thiazolidinedione (2.03%, 11.4% and 11.17%) or anti-diabetic combination (5.2%, 
14.6% and 17.3%), for uninsured, public and private, respectively. Average health 
care resource utilization was lowest among patients without health insurances 
compared to private and public, office visits (4.9, 11.1 and 9.5), outpatient facility 
visits (0.4, 0.9 and 1) and hospital discharge (0.1, 0.3 and 0.2 ). Uninsured patients had 
lower average health care expenditures, ($4,319.5, $10,558.4, $10,377.6), emergency 
room expenditures ($110.4, $253 and $282.9) and office visits expenditures ($832.4, 
$2202.5 and $2414.6), for uninsured, public and private, respectively. ConClusions: 
It is important to assess whether lower resource utilization for uninsured patients 
impacts their current health status and is associated with long term worse out-
comes and increased health care.
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objeCtives: This US study aimed to determine average daily dosing of liraglutide 
from a national payer perspective. Methods: This study utilized 211,184 liraglu-
tide pharmacy claims from the national Truven MarketScan® Database (10/1/2011-
9/30/2012). Patients had type 2 diabetes (DM) diagnoses x 2, no type 1 or gestational 
DM, and were ≥ 18 years old (N= 56,971). Liraglutide is typically dosed in 1.2 and 
1.8 mg/day injections. DACON was based on total daily quantity prescribed (ml 
x 6 mg/ml ÷ days’ supply). A number of claim quantities and days’ supply values 
ranged from negative/zero to very high and implausible values, which translated 
and 0.008 (D1) and 0.003, 0.013, 0.026 and 0.052 (S1) for baseline event rates of 1, 5, 10 
and 20 per year respectively. ConClusions: Nonlinear models of NSHE disutility 
typically show greater benefit per NSHE avoided in subjects with a lower frequency 
of events. As hypoglycaemia frequency increases the marginal utility gain per NSHE 
avoided decreases. Nonlinear equations provide a more plausible estimate of the 
health benefit associated with the avoidance of NSHE.
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objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and previ-
ously validated decision support tool. The model uses the UKPDS 68 risk equations 
(REs) to predict cardiovascular events and recent studies have demonstrated the 
model’s validity to predict event rates consistent with those reported in contem-
porary T2DM outcomes studies. The CDM has been updated to include the new 
UKPDS 82 REs; consequently the objective of this study was to compare the event 
rate predictions from the UKPDS 82 and 68 REs within the CDM. Methods: A total 
of 86 validation simulations were performed to data from ACCORD, ADVANCE, VADT 
and UKPDS. Simulation cohorts mirroring baseline characteristics of each of the 
trials were generated and intensive and conventional treatment arms modeled for 
the relevant study specific follow-up. Predicted versus observed cardiovascular and 
microvascular complications and all-cause mortality (ACM) were assessed using the 
coefficient of determination (R2) goodness of fit measure. Results: Across all vali-
dation studies the CDM simulations produced an R2 statistic of 0.909 using UKPDS 68 
and 0.762 using UKPDS 82. R2 statistic for MI, stroke, CHF, CV death, and ACM were 
0.773, 0.853, 0.499, 0.659 and 0.966 for the UKPDS 68 REs and 0.742, 0.848, 0.852, 0.672 
and 0.88 for the UKPDS 82 REs. Validating against 20-year outcomes data (UKPDS) 
resulted in R2 of 0.992 and 0.993 for UKPDS 68 and 82 respectively. ConClusions: 
The CDM model has been extensively validated using the UKPDS 68 risk equations 
and shown to have good predictive validity. Initial validation using the UKPDS 82 
equations show an improved fit to the UKPDS data, but less accurate external vali-
dation to recent outcomes study trials data. This may be due to necessary assump-
tions applied regarding modifiable risk factor trajectories or the functional form of 
the new equations. Further research is required to assess the robustness of these 
new equations.
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objeCtives: In cost effectiveness (CE) modeling previous studies have dem-
onstrated incorporating parameter sampling is crucial to capture the effects of 
nonlinearity in base case simulation predictions of costs and quality adjusted life 
expectancy (QALE); however, run time requirements (RTR) to reach stabilized predic-
tions may be increased. The objective of this study was to assess the RTR for analy-
ses with parameter sampling necessary to reach predefined end point stabilization 
criteria. Methods: The IMS CORE Diabetes Model was initiated using the following 
type 2 diabetes profile: 55 years of age, duration of diabetes of 5 years and baseline 
HbA1c of 7.49%. Treatment A versus B was assumed to have a 0.5% lower HbA1c 
and incremental treatment cost of $1,500 (USD) with parameter sampling using 
standard errors of 1% of mean. The model was run with 10,000 patients over 10,000 
replications. RTR was assessed in terms of replications required to reach stabiliza-
tion of absolute and incremental costs and QALEs. Stabilization was defined as point 
estimates remaining within the interval of expected value (EV) +/- tolerance (%); 
tolerance was explored in a range of 0.1% to 5% surrounding EV. Results: For total 
costs and QALE the RTR required to reach stabilization was 17 and 44 replications 
respectively for a tolerance of 0.5% and 425 (costs) and 3,459 (QALE) for a tolerance 
of 0.1%. The RTR for stabilized incremental results were considerably greater: 6,886 
and 9,605 replications for costs and QALE respectively at 0.5% tolerance and 9,600 
(costs) and 10,000 (QALE) for a tolerance of 0.1%. ConClusions: Demonstrating 
the stability of simulation output is crucial to ensuring the interpretation of CE 
output is robust. The additional simulation runtime required to achieve stabilized 
incremental results should be factored into simulation study plans and convergence 
of output should be reported routinely.
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objeCtives: Diabetes-related cost-effectiveness analyses (CEA) have become more 
common, though little is known about the actual use of cost-saving services in 
real-world settings. This study systematically reviewed cost-effectiveness analyses 
of diabetes interventions, identified cost-saving diabetes services, and estimated 
potential gains from increasing use of cost-saving diabetes interventions in the 
United States. Methods: We conducted a systematic review of cost-utility analyses 
(CUAs) related to diabetes published through 2012, using the Tufts Medical Center 
CEA Registry. We also examined factors independently associated with favorable 
ratios. We used the 2008-2012 Humedica electronic medical record data to estimate 
the potential cost savings and health benefits gained by switching patients to cost-
saving diabetes interventions identified in our review. Results: We identified 196 
diabetes CUAs. Most examined pharmaceuticals (55%) and focused on treatment 
rather than prevention (70%). Most used a health care payer perspective (71%) and 
were industry-sponsored (52%). Of 497 published cost-utility ratios, 82% examined 
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pitalization were not 80%, and were higher using prescription-based PDC (92%) than 
interval-based PDC (78%).
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objeCtives: To measure the acute-phase persistence and cost of antidepressant 
therapy among commercially insured patients having diabetes. Methods: We 
conducted a retrospective study among patients with diabetes receiving health 
insurance through Blue Cross & Blue Shield of RI between July 1, 2008–December 
31, 2009. New users of antidepressants were defined as having no history of an 
antidepressant dispensing for at least 90 days preceding an incident antidepressant 
prescription. Patients that continued their medication for at least for 90 days were 
classified as persistent. We compared persistence rates according to the therapeutic 
class of antidepressant prescribed, and by users of brand versus generic products. 
A multivariate logistic regression model was developed to predict non-persistence 
with antidepressant therapy by antidepressant type (SSRI/non-SSRI), and by use 
of generic versus brand products. The average total prescription cost for the 90 
day period was calculated and stratified by use of brand or generic antidepres-
sants. Results: We identified 743 patients with diabetes who were newly pre-
scribed an antidepressant; a majority were prescribed SSRI antidepressants (52.5%), 
while 26% were prescribed a brand name antidepressant, and 432 (58%) patients 
were classified as non-persistent. Users of non-SSRI antidepressants were more 
likely to fail to persist (OR 1.57, 95% CI 1.16-2.12). For non-persistent patients, the 
average cost of therapy was $126.70 among users of brand antidepressants, while 
the average cost among users of generics was $17.10. Among persistent patients, 
the average cost among users of brand antidepressants was $461.4, while the aver-
age cost among users of generics was $70.80. ConClusions: In this population 
of commercially-insured patients having diabetes, acute-phase persistence with 
antidepressant therapy was higher among patients prescribed SSRI medications, 
while treatment costs differed substantially among those prescribed brand versus 
generic medications.
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objeCtives: Many retailers offer low cost generic prescriptions, which may mean 
Medicare patients pay cash for at least some Rxs. Plans typically have visibility 
only to adjudicated prescriptions and do not include cash prescriptions in their 
adherence metric. This research investigates whether adherence is actually higher 
than that reported in the Medicare Advantage Star Ratings. Methods: Adheris® 
receives a nationally representative sample of prescription data, collected directly 
from retail pharmacies, containing roughly 40% of all U.S. retail prescription vol-
ume and 130 million unique patient IDs. The HIPAA-compliant, longitudinal data 
captures all prescriptions filled at the pharmacy, including all payment methods. 
The study cohort selected all patients filling at least one non-cash prescription 
in the oral diabetes category between January and September 2013. Patients were 
observed through December 2013. Exclusion criteria used by CMS for the 2013 Part 
D oral diabetes medication adherence metric were employed. Patient eligibility 
(requiring pharmacy use in the last quarter of the observation period) and a constant 
store panel were utilized to ensure completeness of patient data. Medicaid patients 
were excluded. Adherence was calculated using proportion of days covered (PDC). A 
patient is considered adherent if their PDC> = 80%. PDC computed using only non-
cash prescriptions is compared to PDC computed using all prescriptions (including 
cash) to determine the impact of cash prescriptions on average PDC and on the 
percentage of patients considered adherent. Results: In patients 65+ with at least 
1 cash prescription (n= 62,454), including cash prescriptions improves average PDC 
by 14.89% (64.09-78.98%) and the percentage of adherent patients by 19.38% (40.92-
60.30%). In all patients 65+ (n= 483,740), the improvement is 1.92% (76.45-78.38%) 
and 2.50% (58.16-60.66%) respectively. ConClusions: Including cash prescriptions 
improves adherence rates reported by plans as part of the Star Ratings, indicating 
that patients are more adherent than other statistics indicate.
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objeCtives: Dipeptidyl peptidase-4 enzyme inhibitors (DPP-4is) are a class of oral 
antidiabetic medications approved to lower blood glucose in patients with type 2 
diabetes (T2DM). This analysis compared adherence and persistence over 1-year 
and 2-year periods among T2DM patients initiating saxagliptin or sitagliptin, two 
DPP-4is. Methods: Adults with T2DM in the MarketScan® US claims database who 
initiated saxagliptin or sitagliptin (index drug) between 1/1/2009-1/31/2012 with no 
use of DPP-4is in the previous year were included. 1 year continuous enrollment 
pre-initiation and 1 year post-initiation were required. A sub-group of patients had 
2 years of post-initiation enrollment. Adherence was defined as proportion of days 
covered (adherent if ?0.80), and persistence was defined as time to discontinuation 
(end of days’ supply of index drug prior to gap of 60 days). Logistic regression and 
proportional hazards regression models adjusted for demographic, clinical, and pre-
scription characteristics. Results: 11,219 saxagliptin patients and 49,400 sitagliptin 
patients met the study criteria. The subset with 2 years of follow-up consisted of 
3,505 saxagliptin and 27,568 sitagliptin patients. There were significant differences 
to extremely high daily dose results (skewed distribution). The anomalies were 
addressed by conducting several analyses. The primary analysis included quantities 
from 6-27 ml/day and calculated mg/day DACON values as < 0.6, 0.6-1.5= 1.2, > 1.5-
2.1= 1.8, and > 1.8. Sensitivity analyses were conducted for: (A) all values, (B) quantity 
values “corrected” by corresponding price, (C) quantities corresponding exactly to 
1.2 and 1.8 mg/day, (D) quantities with calculated DACONs between 0.6 and 1.8. 
Additional analyses were performed on excluded patients (N= 30,098). Results: On 
average, patients were 55 years old, 53% female, 60% from PPO plans. Comorbidities 
included hypertension (48%), cardiovascular disease (11%), obesity (10%), and neu-
ropathy (9%). The DACON for primary analysis was 1.64 (34.4% at 1.2 mg/day; 64.2% 
at 1.8 mg/day). A sensitivity analysis of all positive claims (A) produced a DACON 
of 1.97 with 3% of claims > 1.8 mg/day; additional DACON analyses were 1.63(B), 
1.64(C), and 1.59(D). DACON primary analysis and all-value (A) analyses on liraglu-
tide patients not meeting inclusion criteria were 1.65 and 1.95. ConClusions: 
Careful inspection of claims data distributions should guide methods used to 
arrive at reasonable, compelling findings for analyses even as simple as DACON. 
Liraglutide’s DACON in use with type 2 DM ranged from 1.59 to 1.64.
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objeCtives: The objective of the study was to measure the health care utiliza-
tion and direct economic burden of diabetic patients covered by urban employee 
basic medical insurance (UEBMI) in urban China. Methods: All diabetic patients 
enrolled in UEBMI in a sample city from 2009 through 2011 were included. Retrieved 
data included patient personal information, complications and co-morbidities 
(CCs), service utilization, total medical expense and expense reimbursed by the 
scheme. Descriptive analysis was employed to examine the service utilization 
and direct economic burden. Results: There were 1695, 1824, and 2088 diabetic 
patients treated in the schemes from 2009 through 2011, respectively. The propor-
tion of women was around 38% each year. The patients aged 50-80 accounted for 
about 80%. The percentages of chronic CCs increased year by year. Neuropathy, 
hypertension, and cardiovascular and cerebrovascular diseases were the top three 
CCs, accounting for 53.83%, 51.63%, and 28.40% in 2011, respectively. 63%-65% 
patients were managed by only oral glucose-lowering treatments. Each patient had 
the average of 30 outpatient visits and 1.5 hospitalization stays each year. In three 
years, average medical expense per patient was RMB 15,387, 16,817 and 18,714, 
respectively. A little more than 30% of total expenses were paid out-of-pocket by 
patients. Medicines accounted for over 74% of total expenses, but medicines for 
glycemic control only occupied 23%. The top 8 products most used for glucose 
control accounted for 79% of total medicine costs, in which, acarbose and met-
formin were ranked as the first two products, amounting to 34% of total medicine 
costs. ConClusions: Chronic CCs in diabetic patients brought higher medical 
service utilization. Direct economic burden and service utilization increased year 
by year. Medicines was the main expense, but used for other purposes rather than 
glycemic control. The rational use of medicines and CCs monitoring and manage-
ment should be promoted in China.
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objeCtives: A number of quality improvement efforts for chronic diseases are 
tied to patients achieving ≥ 80% annual refill adherence. However, there is little 
empirical evidence that this threshold optimally predicts important health out-
comes overall or within different patient sub-groups. The optimal threshold may 
also vary by whether adherence is calculated using interval-based (e.g., measured 
over 365 days) or prescription-based (measured from first through last prescription) 
methods. We used a survival tree model to identify adherence thresholds to oral 
hypoglycemic agents (OHA) most associated with avoidance of hospitalizations in 
different subgroups of diabetes patients. Methods: We obtained prescription drug 
and medical claims for 30,961 Pennsylvania Medicaid enrollees aged 18-64 years 
with diabetes and ≥ 2 OHA fills, who were continuously enrolled for 30 months 
from 2007-2011 (6 months before and 2 years after their first OHA prescription). 
Adherence rates were calculated during year 1 using interval- and prescription-
based proportion of days covered (PDC). Survival tree models were fit to predict risk 
of all-cause hospitalization in year 2, and empirically identify a series of covariate-
based binary split points to derive adherence thresholds that best discriminate 
hospitalization risk. Results: Among the sample (mean age, 49 years; 67% female), 
mean PDCs were 0.64 (interval-based) and 0.77 (prescription-based). Twenty-four 
percent (n= 7,472) of patients had ≥ 1 hospitalization. Among patients with no base-
line hospitalizations or comorbidities, adherence cut points of 78% (interval-based) 
and 92% (prescription-based) optimally differentiated hospitalization risk, result-
ing in a 20% risk reduction with adherence above these levels. For patients with 
baseline hospitalizations or comorbidities, PDC did not significantly predict future 
hospitalization. ConClusions: Refill adherence thresholds may lack predictive 
validity in terms of hospitalization risk for patients with prior hospitalization or 
comorbidities. For healthier patients, adherence thresholds most predictive of hos-
